Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Hua Medicine (2552) operate in?
Hua Medicine belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Hua Medicine (2552) current stock price?
As of the latest data, Hua Medicine stock price is HK$2.34, with a previous close of HK$2.33. Hua Medicine gained HK$0.01 in the last trading session, representing a 0.43% increase.
What is Hua Medicine (2552) current market capitalization?
Hua Medicine market cap is approximately 2.34 billion.
What is Hua Medicine (2552) EBITDA?
Hua Medicine EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.22 million.
Does Hua Medicine (2552) pay dividends?
No. Hua Medicine does not pay a dividend.
What is Hua Medicine (2552) beta (volatility) score?
Hua Medicine has a beta of 0.801, meaning its volatility is roughly in line with the market.
